Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Olufemi Emmanuel Babalola"'
Autor:
Kuburat Oliyide, Olubanke Theodora Ilo, Olufemi Emmanuel Babalola, Tunji Adenekan, Michael Olufemi Kehinde, Aribaba Olufisayo Tade, Folasade Akinsola
Publikováno v:
Nigerian Journal of Medicine, Vol 32, Iss 5, Pp 522-528 (2024)
Introduction: Sickle cell disease has been associated with ocular complications in several studies. However, it has not often been compared with nonhemoglobinopathy controls. Aim: The aim of this study was to determine the ocular complications of sic
Externí odkaz:
https://doaj.org/article/c059b4c9019c42c2b935e56af0a5ec41
Autor:
Olubanke Theodora Ilo, Tunji Sunday Oluleye, Olufemi Emmanuel Babalola, Adetunji Olusesan Adenekan, Folasade Bolanle Akinsola
Publikováno v:
Nigerian Journal of Medicine, Vol 30, Iss 4, Pp 419-425 (2021)
Background: Globally, there is still much to learn about the evolving coronavirus disease 2019 (COVID-19) virus, its transmission, prevention, and treatment. Therefore, this study investigates the knowledge, perception, and screening practices of COV
Externí odkaz:
https://doaj.org/article/b532215975a44e7595aa4bb787ef8285
Autor:
Olufemi Emmanuel Babalola
Publikováno v:
American Journal of Ophthalmology Case Reports, Vol 20, Iss , Pp 100974- (2020)
Purpose: Linezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including Streptococcus, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-res
Externí odkaz:
https://doaj.org/article/cb5a811a079245a183764aece8b5126c
Autor:
olufemi Emmanuel Babalola, Adesuyi A. Ajayi, Thairu Yunusa, Yahaya Ndanusa, John O. Ogedengbe, Omede Ogu
Background and Objectives: Hypoxemic respiratory failure is a common mode of demise in Covid 19 disease. We aimed to describe the time course of SPO2 changes in Covid 19 patients treated with and without ivermectin.Methods: This was a parallel group,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ae1ff6fb68f53ff683ae86808010cbb
https://doi.org/10.21203/rs.3.rs-1576399/v1
https://doi.org/10.21203/rs.3.rs-1576399/v1
Autor:
Olufemi Emmanuel Babalola, John O. Ogedengbe, Ndanusa Yahaya, Ogu Omede, Yunusa Thairu, A. Adesuyi Ajayi
The efficacy of ivermectin (IVM) against SARS-CoV-2 has been demonstrated in vitro, while several clinical studies suggest that it is efficacious and safe in reducing morbidity and mortality. Hydroxychloroquine HCQ, IVM and azithromycin AZM (HIA ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::954165ff4a147caa843be06a642db7b4
https://doi.org/10.21203/rs.3.rs-950352/v1
https://doi.org/10.21203/rs.3.rs-950352/v1
Autor:
Andrew Hill, Ahmed Abdulamir, Sabeena Ahmed, Asma Asghar, Olufemi Emmanuel Babalola, Rabia Basri, Carlos Chaccour, Aijaz Zeeshan Khan Chachar, Abu Tauib Mohammed Chowdhury, Ahmed Elgazzar, Leah Ellis, Jonathan Falconer, Anna Garratt, Basma Hany, Hashim A Hashim, Wasim Ul Haque, Arshad Hayat, Shuixiang He, Ramin Jamshidian, Wasif Ali Khan, Ravi Kirti, Alejandro Krolewiecki, Carlos Lanusse, Jacob Levi, Reaz Mahmud, Sermand Ahmed Mangat, Kaitlyn McCann, Anant Mohan, Mortezza Shakshi Niaee, Nurullah Okumus, Victoria Pilkington, Chinmay Saha Podder, Ambar Qavi, Houssam Raad, Mohammaed Sadegh Rezai, Surapaneni Sasank, Veerapaneni Spoorthi, Tejas Suri, Junzheng Wang, Hannah Wentzel
Ivermectin is an antiparasitic drug being investigated for repurposing to SARS-CoV-2. In-vitro, ivermectin showed limited antiviral activity and a COVID-19 animal model demonstrated pathological benefits but no effect on viral RNA. This meta-analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efcc6d80423cf6cc9688126d8d0c8e7b
https://doi.org/10.21203/rs.3.rs-148845/v1
https://doi.org/10.21203/rs.3.rs-148845/v1
Autor:
Adesoji O Ademuyiwa, Erere Otrofanowei, Wasiu Lanre Adeyemo, O.B. Salu, Felix M Alakaloko, Iorhen E. Akase, A. A. Ajayi, Olufemi Emmanuel Babalola, Christopher O Bode, Sunday Omilabu
IntroductionIn vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS - CoV-2 viral replication, but questions remained as to In-vivo applications. We set out to explore the efficacy and safety of Ivermectin in persons infected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a3b5cbd1a59dabd0741df7fc7020912
https://doi.org/10.1101/2021.01.05.21249131
https://doi.org/10.1101/2021.01.05.21249131
Autor:
F B Akinsola, Olubanke Theodora Ilo, Adetunji Olusesan Adenekan, Olufemi Emmanuel Babalola, Tunji S Oluleye
Publikováno v:
Nigerian Journal of Medicine, Vol 30, Iss 4, Pp 419-425 (2021)
Background: Globally, there is still much to learn about the evolving coronavirus disease 2019 (COVID-19) virus, its transmission, prevention, and treatment. Therefore, this study investigates the knowledge, perception, and screening practices of COV
Autor:
Amos Bassi, Olufemi Emmanuel Babalola
Publikováno v:
The Nigerian postgraduate medical journal. 24(1)
Purpose: To assess the impact on blindness after 27 years of community-directed treatment with ivermectin (CDTI) in the Galadimawa community of Kauru Local Government in Kaduna state, Nigeria. The population of Galadimawa constituted about 12% of the
Publikováno v:
Clinical Ophthalmology, Vol 2013, Iss default, Pp 2275-2279 (2013)
Clinical Ophthalmology (Auckland, N.Z.)
Clinical Ophthalmology (Auckland, N.Z.)
OE Babalola,1 A Adu,2 AO Akano3 1Bingham University, New Karu, Nassarawa State, 2Department of Ophthalmology, Rachel Eye Center, Garki Phase II, 3Department of Radiology, National Hospital, Abuja, Nigeria Abstract: We report the case of a 32-year-old